metformin has been researched along with sitagliptin phosphate in 356 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 36 (10.11) | 29.6817 |
2010's | 252 (70.79) | 24.3611 |
2020's | 68 (19.10) | 2.80 |
Authors | Studies |
---|---|
Bergman, A; Herman, GA; Kipnes, M; Yi, B | 1 |
Charbonnel, B; Karasik, A; Liu, J; Meininger, G; Wu, M | 1 |
Brazg, R; Cobelli, C; Dalla Man, C; Stein, PP; Thomas, K; Xu, L | 1 |
Meininger, G; Nauck, MA; Sheng, D; Stein, PP; Terranella, L | 1 |
Drucker, D; Easley, C; Kirkpatrick, P | 1 |
Feinglos, MN; Goldstein, BJ; Johnson, J; Lunceford, JK; Williams-Herman, DE | 1 |
Eldor, R; Raz, I | 1 |
Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P | 1 |
Whitehill, D | 1 |
Mirza, SA | 1 |
Gallwitz, B | 1 |
Ahrén, B | 3 |
Aschner, P; Davies, MJ; Karasik, A; Katzeff, H; Stein, PP | 1 |
Alba, M; Amatruda, JM; Chen, Y; Hussain, S; Kaufman, KD; Langdon, RB; Raz, I; Stein, PP; Wu, M | 1 |
Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
Nogid, A; Pham, DQ; Plakogiannis, R | 1 |
Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D | 1 |
Charbonnel, B; Cobelli, C; Davies, MJ; Man, CD; Meninger, G; Stein, PP; Williams-Herman, D; Xu, L | 1 |
Campbell, RK; Neumiller, JJ; Reynolds, JK | 1 |
Feinglos, M; Green, J | 1 |
Amatruda, JM; Davies, MJ; Goldstein, BJ; Johnson, J; Kaufman, KD; Luo, E; Teng, R; Williams-Herman, D | 1 |
Arnold Chan, K; Dore, DD; Seeger, JD | 1 |
Butler, AE; Butler, PC; Cox, HI; Dry, S; Galasso, R; Gurlo, T; Matveyenko, AV; Moshtaghian, A | 1 |
Keating, N | 1 |
Matthaei, S | 1 |
Bischoff, A | 1 |
Henson, K; Hight, R; Welborn, D; Wyatt, S | 1 |
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
Alexander, CM; Siler, SQ; Topp, BG; Waters, SB | 1 |
Aschner, P; Goldstein, BJ; Guo, H; Katzeff, HL; Kaufman, KD; Sunga, S; Williams-Herman, D | 1 |
Amatruda, JM; Andryuk, PJ; Cefalu, WT; Chen, Y; Engel, SS; Katz, L; Kaufman, KD; Ling, Y; Luo, E; Musser, B; Rosenstock, J; Vilsbøll, T; Yki-Järvinen, H | 1 |
Ban, K; Drucker, DJ; Henkelman, RM; Husain, M; Momen, MA; Sauvé, M; Zhou, YQ | 1 |
Meier, JJ; Menge, BA; Schmidt, WE | 1 |
Agostini, C; Albiero, M; Avogaro, A; Boscaro, E; de Kreutzenberg, S; Fadini, GP; Frison, V; Menegazzo, L; Tiengo, A | 1 |
Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T | 1 |
Freeman, JS | 1 |
Scheen, AJ; Van Gaal, LF | 2 |
Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
Amatruda, JM; Goldstein, BJ; Golm, G; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D | 1 |
Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Montanya, E; Nauck, M; Pratley, RE; Søndergaard, RE; Thomsen, AB | 1 |
Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S | 1 |
Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P | 1 |
Meier, JJ; Nauck, MA | 1 |
Scheen, AJ | 2 |
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ | 1 |
Ahn, SH; Bae, MA; Choi, MK; Jin, QR; Song, IS | 1 |
Opsteen, C; Qi, Y; Retnakaran, R; Vivero, E; Zinman, B | 1 |
Gottesdiener, KM; Gutierrez, M; Johnson-Levonas, AO; Liu, Q; Matthews, CZ; Migoya, EM; Miller, JL; Wagner, JA; Zheng, W | 1 |
Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D | 1 |
Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV | 1 |
Seyoum, B | 1 |
Cuddihy, R; Davies, M; Hammer, M; Pratley, R; Thomsen, AB | 1 |
Chwieduk, CM | 1 |
Choi, SE; Han, SJ; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Yi, SA | 1 |
Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB | 1 |
Chen, M; Goldstein, BJ; Johnson-Levonas, AO; Kaufman, KD; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE | 1 |
Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
Denn, M; Gallagher, RT; Peter, RM; Swales, JG | 1 |
Daniela, L; Ludvik, B | 1 |
Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Seck, TL; Sisk, CM; Wang, H; Williams-Herman, DE | 1 |
Chen, M; Goldstein, BJ; Kaufman, KD; Mehta, A; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE | 1 |
Ayoub, BM; El-Bagary, RI; Elkady, EF | 1 |
Engel, SS; Goldstein, BJ; Kaufman, KD; Lee, MA; Pérez-Monteverde, A; Seck, T; Sisk, CM; Williams-Herman, DE; Xu, L | 1 |
Chubb, BD; Davies, MJ; Smith, IC; Valentine, WJ | 1 |
Jermendy, G | 2 |
Ahn, HY; An, JH; Cho, YM; Choi, SH; Jang, HC; Kang, SM; Khang, AR; Lee, Y; Lim, S; Park, KS; Shin, H; Yoon, JW | 1 |
Davies, MJ; Goldstein, BJ; Golm, GT; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D; Xu, L | 1 |
Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y | 1 |
Engel, SS; Goldstein, BJ; Golm, GT; Hussain, S; Katz, L; Kaufman, KD; O'Neill, EA; Wainstein, J; Xu, L | 1 |
Aso, Y; Hara, K; Haruki, K; Inukai, T; Morita, K; Naruse, R; Ozeki, N; Shibazaki, M; Suetsugu, M; Takebayashi, K; Terasawa, T | 1 |
Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM | 1 |
Briand, F; Burcelin, R; Sulpice, T; Thieblemont, Q | 1 |
Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB | 1 |
Nauck, MA | 1 |
Berman, S; Efrati, S; Golik, A; Hamad, RA; Koren, S; Peleg, RK; Shemesh-Bar, L; Tirosh, A; Vinker, S | 1 |
Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
Alba, M; Engel, SS; Goldstein, BJ; Guan, Y; Johnson-Levonas, AO; Kaufman, KD; Li, Z; Shentu, Y; Yang, W | 1 |
Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E | 1 |
Diamant, M | 1 |
Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR | 1 |
Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D | 1 |
Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE | 1 |
Daskiran, M; Dickson, WM; Kozma, CM; Nigam, S; Paris, A; Virdi, NS | 1 |
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
Arafat, T; Idkaidek, N | 1 |
Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S | 1 |
Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P | 1 |
Langer, J; Lee, WC; Palmer, JL; Samyshkin, Y | 1 |
Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB | 1 |
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F | 2 |
Inazumi, T; Kimura, M; Komatsu, Y; Kondo, Y; Nakamura, A; Tajima, K; Takihata, M; Tamura, H; Terauchi, Y; Yamada, M; Yamazaki, S | 1 |
Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
Bakris, GL; Flynn, C | 1 |
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 2 |
Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E | 1 |
Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M | 1 |
Gavish, D; Gevrielov-Yusim, N; Goldenberg, I; Gottlieb, S; Leibovitz, E; Matetzky, S | 1 |
Hunt, B; Langer, J; Valentine, WJ | 1 |
Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C | 1 |
Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L | 1 |
Schütt, M; Steinhoff, J; Süfke, S | 1 |
Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D | 1 |
Bruce, SS; Connolly, ES; Heyer, EJ; Mergeche, JL | 1 |
Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S | 1 |
Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY | 1 |
Derosa, G; Maffioli, P | 1 |
Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A | 1 |
Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
Cho, JH; Kim, ES; Kim, HS; Lee, SH; Shin, JA; Son, HY; Yoon, KH | 1 |
Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
Arndt, E; Deacon, CF; Holst, JJ; Nauck, MA; Vardarli, I | 1 |
Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ | 1 |
Li, H; Lu, J; Zang, J | 1 |
Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J | 1 |
Fathy, A; Khashab, S; Shaheen, N; Soliman, AR; Soliman, MA | 1 |
Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
Cunningham, C; Dey, M; Forest, T; Frederick, C; Holder, D; Prahalada, S; Smith, A; Yao, X | 1 |
Schnell, O | 1 |
Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
Arai, K; Hirao, K; Hirao, S; Hirao, T; Kumakura, A; Maeda, H; Shirabe, S; Yamamoto, R; Yamauchi, M | 1 |
Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
Ferrannini, E; Mari, A; Polidori, D | 1 |
Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z | 1 |
Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK | 1 |
Hegazy, SK | 1 |
Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T | 1 |
Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS | 1 |
Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F | 1 |
Persson, U; Steen Carlsson, K | 1 |
Ban, N; Kawana, H; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Yamaguchi, T | 1 |
Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
Ametov, AS; Gusenbekova, DG | 1 |
Furukawa, A; Ishihara, H; Kosuda, M; Nakazaki, M; Otsuka, Y; Yamaguchi, S | 1 |
Carpenter, KH; Chisholm, DJ; Coster, AC; Greenfield, JR; Gribble, FM; Holst, JJ; Jones, GR; Samocha-Bonet, D | 1 |
Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
Andersen, H; Hiort, LC; Linjawi, S; Rao, P; Sari, R; Sothiratnam, R | 1 |
Baik, SH; Choi, SH; Chung, CH; Jin, SM; Kim, DM; Lee, HW; Lee, IK; Lee, MK; Min, KW; Park, IB; Park, JY; Park, KS; Park, SW; Song, KH; Yoon, KH | 1 |
Thompson, AM; Trujillo, JM | 1 |
Amin, NB; Jain, SM; Lee, DS; Nucci, G; Rusnak, JM; Wang, X | 1 |
Dong, Q; Engel, SS; Goldstein, BJ; Golm, GT; Johnson, JR; Katzeff, HL; Kaufman, KD; O'Neill, EA; Wang, H; Williams-Herman, D; Xu, L | 1 |
Aggarwal, N; Amin, NB; Calle, RA; Denney, WS; Le, V; Pall, D; Paragh, G; Riggs, M | 1 |
Guerci, B; Milicevic, Z; Nauck, MA; Skrivanek, Z; Umpierrez, G; Weinstock, RS | 1 |
Drzewoski, J; Kasznicki, J; Marczak, A; Rogalska, A; Sliwinska, A | 2 |
Blonde, L; Brodovicz, KG; Brudi, P; Engel, SS; Fan, CP; Hanna, B; Inzucchi, SE; Li, Z; Mavros, P; Qiu, Y; Radican, L; Rajpathak, S; Tang, J; Tunceli, K | 1 |
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M | 1 |
Benard, N; Chanut-Vogel, C; Dallongeville, J; de Pouvourville, G; Eymard, E; Kempf, C; Moisan, C; Valensi, P | 1 |
Lotfy, HM; Mohamed, D; Mowaka, S | 1 |
Ahmad, I; Ahmed, I; Mukhopadhyay, A; Reddy, S; Thangam, S | 1 |
Ahrén, B; Cho, YM; Choi, SH; Jang, HC; Jung, KY; Kim, KM; Kim, YJ; Ku, EJ; Lim, S; Moon, JH; Park, KS | 1 |
Huang, X; Liu, Z; Rajpathak, S; Shankar, RR | 1 |
Högger, P; Scherf-Clavel, M | 1 |
Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
Federici, M; Kappel, BA; Marx, N | 1 |
Afzal, A; Ashraf, H; Bajwa, SZ; Haq, I; Hussain, T; Iqbal, N; Mujahid, A; Shehzad, K | 1 |
Fath, R | 1 |
D'Angelo, A; Derosa, G; Maffioli, P | 1 |
Balladares, N; Contreras, M; D'Marco, L; Iacobellis, G; Lima-Martínez, MM; Paoli, M; Rodney, M | 1 |
Brouwers, PJ; den Hertog, HM; Dippel, DW; Fonville, S; Koudstaal, PJ; Lingsma, HF; Mulder, LJ; Osei, E; Zandbergen, AA | 1 |
Brown, C; Chastain, LM; Maggu, GA; Vuylsteke, V | 1 |
Dungan, KM; Fahrbach, JL; Raz, I; Sealls, W; Skrivanek, Z | 1 |
Ferrario, MG; Lizán, L; Montagnoli, R; Ramírez de Arellano, A | 1 |
Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C | 1 |
Engel, SS; Gantz, I; Goldstein, BJ; Golm, GT; Kaufman, KD; Moses, RG; O'neill, EA; Round, E; Shentu, Y | 1 |
Chen, C; Li, L; Li, M; Li, Y; Ou, M; Xu, X | 1 |
Tong, N; Zhang, L; Zhang, M; Zhang, Y | 1 |
García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G | 1 |
Geurin, MD | 1 |
Cao, J; Ji, M; Xia, L; Zou, D | 1 |
Bian, F; Bosch-Traberg, H; Geng, J; Li, Y; Liu, J; Liu, Y; Luo, Y; Lv, X; Mu, Y; Peng, Y; Sun, Y; Yang, J; Zang, L | 1 |
Ferenci, T; Simonyi, G | 1 |
Aggarwal, N; Alba, M; Cao, A; Fung, A; Pfeifer, M; Rodbard, HW; Seufert, J | 1 |
Engel, SS; Golm, GT; Han, P; Ji, L; Jou, YM; Kaufman, KD; Liu, J; O'Neill, EA; Shankar, RR; Wang, X; Zheng, S | 1 |
Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH | 1 |
Georgy, A; Liang, Z; Zhai, S; Zhi, J | 1 |
Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 2 |
Bailey, TS; Kaltoft, MS; Maislos, M; Rao, PV; Takács, R; Thomsen, AB; Tinahones, FJ; Tsoukas, GM | 1 |
Canovatchel, W; Davidson, JA; Jodon, H; Lavalle-González, FJ; Qiu, R; Schernthaner, G; Vijapurkar, U | 1 |
Cahen, DL; Diamant, M; Groen, AK; Hoekstra, T; Kramer, MH; Muskiet, MH; Nieuwdorp, M; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
Johansen, P; Neslusan, C; Sabapathy, S; Teschemaker, A; Willis, M; Yoong, K | 1 |
Anderson, R; Hayes, J; Stephens, JW | 1 |
Ba, J; Engel, SS; Han, P; Hanson, ME; Mo, Z; Pan, C; Shankar, RR; Wu, F; Xu, L; Yuan, G | 1 |
Sanyal, M; Shah, JV; Shah, PA; Shrivastav, PS | 1 |
Bloomgarden, ZT; Brodovicz, KG; Brudi, P; Chen, Y; Engel, SS; Fonseca, V; Liu, J; Mavros, P; Qiu, Y; Radican, L; Rajpathak, S; Tunceli, K | 1 |
Anzola, I; Duan, W; Hudson, M; Pasquel, FJ; Peng, L; Smiley, DD; Stefanovski, D; Umpierrez, GE; Vellanki, P | 1 |
Adler, A; Armstrong, PW; Bethel, MA; Buse, JB; Green, JB; Holman, RR; Josse, RG; Kaufman, KD; Majumdar, SR; Peterson, ED; Rodbard, HW; Tankova, T; Westerhout, CM; Zheng, Y | 1 |
Aoki, S; Atsumi, T; Furumoto, T; Inoue, A; Kurihara, Y; Manda, N; Miyoshi, H; Nomoto, H; Oba, K; Tsutsui, H | 1 |
Bao, Y; Engel, SS; Han, P; Hu, J; Jia, W; Ma, J; Peng, Y; Shankar, RR; Wu, F; Xu, L | 1 |
Arturi, F; Gallelli, L; Palleria, C; Ruffo, M; Serra, R; Succurro, E | 1 |
Torjesen, I | 1 |
Aggarwal, R; Jaggi, S; Juneja, D; Saraswat, V; Sehra, D; Sehra, S | 1 |
Amin, NB; Denham, DS; Denney, WS; Riggs, MR | 1 |
Demir, S; Sargin, M; Temizkan, S | 1 |
Alegria, V; Andres, I; Fuertes, L; Gimeno, I; Lopez, J; Macias, E; Perez, A; Perez, Y; Ramírez-Bellver, JL; Requena, L | 1 |
Abd-Elaziz, LF; Aboul-Fotouh, S; El-Kharashi, OA; Magdy, YM; Nabih, ES; Shaker, SM | 1 |
Engel, SS; Fujita, KP; Kaufman, KD; Liu, X; Ma, J; Ning, G; O'Neill, EA; Shankar, RR; Wang, W; Wu, F; Xu, L; Zheng, S | 1 |
Chung, CH; Han, KA; Hong, SM; Hwang, DM; Lee, CB; Mok, JO; Park, CY; Park, KS; Park, SW; Yoon, KH | 1 |
Cho, JH; Hur, GC; Jang, YH; Jung, CH; Kim, JH; Kim, SH; Lee, BW; Lee, SH; Lee, WJ; Park, CY; Park, SE; Suh, S | 1 |
Andryuk, PJ; Engel, SS; Gantz, I; Goldenberg, R; Kaufman, KD; Lai, E; O'Neill, EA; Suryawanshi, S; Wang, YN | 1 |
Branum, A; Malik, M; Puppala, VK; Signorelli, K; Suboc, TM; Tanner, MJ; Tyagi, S; Wang, J; Widlansky, ME; Ying, R | 1 |
Atif, MA; Ghafoor, MB; Hussain, M | 1 |
Miyagi, K; Mutoh, A; Takasu, N; Yabiku, K | 1 |
Gadde, KM; Hardy, E; Iqbal, N; Öhman, P; Vetter, ML | 1 |
Cao, C; Marcinak, JF; Peng, XV; Raanan, MG | 1 |
Jung, K; Shah, N; Vashisht, R | 1 |
Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D | 1 |
Anglin, G; Barkin, JS; Frossard, JL; Harper, KD; Hensley, IE; Milicevic, Z; Nauck, MA | 1 |
Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D | 1 |
Lingvay, I | 1 |
Chen, W; Liu, X; Mei, T; Ye, S | 1 |
El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MAEM | 1 |
Chmelik, M; Harreiter, J; Kautzky-Willer, A; Kosi-Trebotic, L; Thomas, A; Trattnig, S | 1 |
Li, H; Li, S; Wang, R; Zhang, JP | 1 |
Amorin, G; Dagogo-Jack, S; Eldor, R; Engel, SS; Golm, G; Hille, D; Huyck, S; Johnson, J; Lauring, B; Liao, Y; Liu, J; Mancuso, JP; Terra, SG | 1 |
Jiang, D; Li, M; Wang, Y; Yang, Y; Ying, M; Zhao, R | 1 |
Beckley, N; Nazareth, I; Petersen, I; Sharma, M | 1 |
Eldor, R; Engel, SS; Golm, G; Huyck, SB; Johnson, J; Lauring, B; Mancuso, JP; Pratley, RE; Qiu, Y; Raji, A; Sunga, S; Terra, SG | 1 |
Chung, CH; Jang, HC; Jung, CH; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
Markham, A | 1 |
Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Shaler, D | 1 |
Ahrén, B; Farngren, J; Persson, M | 1 |
Ejima, T; Nagao, T; Wakisaka, M; Yoshizumi, H | 1 |
Alvey, C; Cutler, DL; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, S | 1 |
Dalal, K; Ganguly, B; Gor, A | 1 |
Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M | 1 |
Baik, S; Cha, BS; Chon, S; Chung, CH; Han, KA; Jung, CH; Kim, DS; Lee, IK; Lee, KW; Lee, MK; Lim, S; Park, KS; Park, S; Sakatani, T; Yoon, KH | 1 |
Anzola, I; Dungan, KM; Gianchandani, RY; Gomez, P; Hodish, I; Iyengar, J; Lathkar-Pradhan, S; Pasquel, FJ; Rubin, DJ; Umpierrez, GE; Vellanki, P; Wang, H | 1 |
Fajtova, V | 1 |
Abbas, NAT; El Salem, A | 1 |
Al-Amin, MA; Al-Damry, NT; Al-Rasheed, NM; Atteya, M; Attia, HA; Dizmiri, N; Mohamad, RA | 1 |
Frias, JP; McPheeters, JT; Parker, ED; Wittbrodt, ET | 1 |
Chen, G; Engel, SS; Lin, J; Liu, S; O'Neill, EA; Shankar, RR; Tu, Y; Yu, M; Zhang, R; Zhang, Y | 1 |
Deng, H; Dou, J; Hong, T; Huang, Q; Kang, Z; Kuang, H; Li, Y; Luo, S; Qin, G; Shan, Z; Tan, Y; Weng, J; Xiao, X; Xu, F; Xu, W; Yan, J; Yang, W; Yang, X; Yao, B; Yuan, H; Zeng, L | 1 |
Choi, KM; Jang, HC; Kang, ES; Kim, DJ; Kim, ES; Kim, NH; Kim, SJ; Kim, SR; Kim, Y; Lee, MK; Oh, T; You, J | 1 |
Lansang, MC | 1 |
Darmiento, C; Duran-García, S; Engel, SS; Gantz, I; Golm, GT; Kaufman, KD; Lam, RLH; O'Neill, EA; Roussel, R; Shah, S; Shankar, RR; Zhang, Y | 1 |
Bass, A; Dawra, VK; Fediuk, DJ; Hickman, A; Krishna, R; Liang, Y; Matschke, K; Sahasrabudhe, V; Shi, H; Terra, SG; Zhou, S | 1 |
Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J | 1 |
Bachmann, HS; Besser, M; Koester, V; Severing, AL; Stuermer, EK; Terberger, N | 1 |
Afarideh, M; Alemi, H; Asadi Komeleh, S; Esteghamati, A; Esteghamati, S; Khaloo, P; Mansournia, MA; Mohammadi, A; Nakhjavani, M; Yadegar, A | 1 |
Bilir, SP; Davies, G; Gonzalez, C; Kowal, S; Pawaskar, M; Rajpathak, S | 1 |
Amorin, G; Crutchlow, MF; Engel, SS; Frias, JP; Iredale, C; Kaufman, KD; Lam, RLH; Makimura, H; Ntabadde, C; O'Neill, EA; Zimmer, Z | 1 |
Frias, JP | 1 |
Weng, J | 1 |
Upala, S | 1 |
Allison, D; Birkenfeld, AL; Blicher, TM; Davies, M; Deenadayalan, S; Jacobsen, JB; Rosenstock, J; Serusclat, P; Violante, R; Watada, H | 1 |
Hirsch, IB | 1 |
Aguirre, C; Arion, A; Ayala, I; Cárceles-Rodríguez, CM; Fernández-Varón, E; Martín-Gimenez, T; Rodríguez, MJ | 1 |
Kuhad, A; Razdan, K; Sharma, R | 1 |
Baba, Y; Hashimoto, N; Hattori, A; Horikoshi, T; Ide, K; Ide, S; Ishibashi, R; Ishikawa, K; Ishikawa, T; Kitamoto, T; Kobayashi, A; Kobayashi, K; Koshizaka, M; Maezawa, Y; Nagashima, K; Nakamura, S; Newby, LK; Ogino, J; Ohara, E; Onishi, S; Sakamoto, K; Sato, Y; Shimada, F; Shimofusa, R; Shoji, M; Takahashi, S; Takemoto, M; Tokuyama, H; Uchida, D; Yamaga, M; Yokoh, H; Yokote, K | 2 |
Cusi, K | 1 |
Bai, R; Du, J; Liu, D; Shi, C; Wang, H; Wang, Y; Zhang, R; Zhang, X | 1 |
Catena, G; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D; Tritto, I | 1 |
Freeman, MW; Halvorsen, YD; Lock, JP; Zhou, W; Zhu, F | 1 |
Fuhr, U; Kinzig, M; Scherf-Clavel, O; Sörgel, F; Stoffel, MS | 1 |
Shang, J; Wang, Q; Zhang, Y; Zhou, W | 1 |
Lipscombe, LL | 1 |
Ben Nasr, M; Fiorina, P; Loretelli, C; Malvandi, AM; Zuccotti, GV | 1 |
Taneja, V | 1 |
Weng, J; Yan, J; Yang, D | 1 |
Campbell, SA; Light, PE; Simpson, SH | 1 |
Feng, R; Liu, W; Ma, J; Qian, C; Wang, Z; Yang, M; Zhang, M | 1 |
Almajaan, A; Andrews, GP; Gilvary, GC; Healy, AM; Jones, DS; Kelleher, JF; Li, S; Loys, ZS; Madi, AM; Tian, YW | 1 |
Jackuliak, P; Killinger, Z; Kužma, M; Payer, J | 1 |
Davies, MJ; Kim, KM; Ku, EJ; Lee, JE; Lee, JH; Lee, SY; Lim, S | 1 |
Moradi, M; Mortazavinik, S; Sohrabi, MR | 1 |
Cui, L; Hao, Z; Li, G; Sun, Y; Yan, D | 1 |
Feng, R; Liu, W; Ma, J; Qian, C; Rayner, CK; Yang, M; Yue, J; Zhang, M | 1 |
Bolze, S; Fouqueray, P; Perrimond-Dauchy, S | 1 |
Chen, G; Engel, SS; Ji, Q; Liu, S; Liu, X; Wang, L; Weng, J; Xing, Y; Xu, W; Yao, B; Zeng, L; Zhang, R; Zhang, Y | 1 |
Cha, BS; Choi, DS; Choi, KM; Chun, SW; Kim, DM; Kim, KJ; Kim, MK; Kim, SG; Lee, HW; Lim, S; Mok, JO; Park, KS; Seo, JA; Shon, HS; Yoon, KH | 1 |
Daneshjou, D; Shariat Zadeh, SMA; Soleimani Mehranjani, M; Zadeh Modarres, S | 1 |
Baggio, LL; Cao, X; Drucker, DJ; Holman, RR; Koehler, JA; Lokhnygina, Y; Stevens, SR; Varin, EM | 1 |
Cortese, V; Davies, MJ; Jacquot, E; Khunti, K; Seidu, S; Tyrer, F; Zaccardi, F | 1 |
Ferrannini, E; Katsiki, N | 1 |
Hansen, HS; Jessen, JB; Johannsen, ML; Munkboel, CH; Styrishave, B | 1 |
Daneshjou, D; Shariatzadeh, MA; Soleimani Mehranjani, M; Zadeh Modarres, S | 1 |
Alsumali, A; Briggs, A; Davies, G; Kowal, S; Lautsch, D; Li, Q; Rajpathak, S; Wehler, E | 1 |
Fujihara, K; Furukawa, K; H Yamada, M; Hatta, M; Ikarashi, T; Iwanaga, M; Katagiri, T; Kitazawa, M; Matsunaga, S; Sone, H; Suzuki, H; Tanaka, S; Yamada, T; Yamamoto, M | 1 |
Belzer, C; Cahen, DL; Davids, M; de Vos, WM; Fluitman, KS; Groen, AK; Herrema, H; Kramer, MHH; Nieuwdorp, M; Smits, MM; van Raalte, DH | 1 |
Engel, SS; Kadowaki, T; Kaku, K; Kaufman, KD; O'Neill, EA; Okamoto, T; Sato, A; Seino, Y; Shirakawa, M | 2 |
Nunes, A; Rojas, G | 1 |
Fu, BY; Wang, XJ | 1 |
Ismail, K; Moulton, CD; Pickup, JC; Rokakis, AS; Stahl, D; Young, AH | 1 |
Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P | 1 |
Abdul-Azim Mohammad, M; Elkady, EF; Fouad, MA; Salem, WA | 1 |
Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A | 1 |
Barbosa, AM; Dos Santos, C; Ferreira, FBD; Figueiredo, BS; Ortsäter, H; Rafacho, A | 1 |
Chien, KL; Wang, J; Wu, HY | 1 |
Braga, M; Gerstein, HC; Goldenberg, R; Gupta, N; Hall, S; Hramiak, I; Liu, YY; McInnes, N; Otto, R; Rabasa-Lhoret, R; Sherifali, D; Sigal, RJ; Smith, A; Sultan, F; Woo, V | 1 |
Deeb, A; Engel, SS; Garcia, R; Golm, GT; Jalaludin, MY; Kaufman, KD; Lam, RLH; Newfield, RS; Rosario, CA; Saha, CK; Samoilova, Y; Scherer, LW; Shankar, RR; Shehadeh, N; Zeitler, P; Zhang, Y; Zilli, M | 2 |
Cao, Y; Fu, Y; Gao, XM; Li, T; Liu, SQ; Liu, X; Liu, YP; Ma, YP; Shi, P; Sun, FF | 1 |
Chen, FW; Hou, KJ; Khan, BA; Wu, Z; Wu, ZZ; Zhang, S | 1 |
Ferrannini, E; Lim, S; Shin, Y; Sohn, M | 1 |
Abdallah, FF; Abdelaleem, EA; Emam, AA; Magdy, F | 1 |
Daneshjou, D; Mehranjani, MS; Mofarahe, ZS; Shariatzadeh, SMA; Zadehmodarres, S | 1 |
Aftab, T; Ali, I; Bedar, R; Hanif, S; Iqbal, J; Murtaza, SH; Raza, A; Shakir, R; Syed, MA | 1 |
Cui, W; Kong, L; Yang, X; Zhou, ST | 1 |
Arapieva, AM; Bobrik, AG; Bobrik, DV; Khamitova, AD; Kuznetsov, KO; Mahmutova, EI; Nagaev, IR; Saetova, AA | 1 |
Cheng, MZ; Gao, Y; Liu, L; Zhan, ZT; Zhou, WJ | 1 |
Feng, Y; Ge, Y; He, Y; Hou, L; Huo, M; Ji, Y; Li, H; Liu, X; Liu, Y; Luo, Q; Qian, F; Wang, J; Wei, Y; Wu, S; Wu, Y; Xue, F; Yu, Y | 1 |
Qu, S; Sun, H; Wang, X; You, H; Zhao, B | 1 |
Balasubramanyam, A; Burch, HB; Buse, JB; Butera, NM; Cohen, RM; Crandall, JP; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Rasouli, N; Tiktin, M; Wexler, DJ; Younes, N | 1 |
Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N | 1 |
Crown, W; Deng, Y; Dhruva, SS; Gandotra, C; Herrin, J; Lyon, TD; McCoy, RG; Noseworthy, P; Polley, EC; Quinto, K; Ross, JS; Shah, ND; Wallach, JD; Yao, X | 1 |
Aamir, AH; Ahmed, I; Asghar, A; Ghaffar, T; Ishtiaq, O; Khan, S; Kumar, S; Masood, F; Raja, UY; Randhawa, FA; Raza, A; Rehman, T; Sherin, A; Wahab, MU | 1 |
Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ | 1 |
Ahmed, A; Ali, M; Fazal-Ur-Rehman, S; Wasim, AA | 1 |
Angwin, CD; Britten, N; Hattersley, AT; Holman, R; Jones, AG; Pearson, ER; Sattar, N; Shepherd, MH; Shields, BM | 1 |
Athar, M; Garg, A; Khan, MA; Kohli, S; Parveen, R; Vohora, D | 1 |
Ahn, KJ; Choi, KM; Chung, CH; Jang, HC; Kim, DM; Kim, SG; Kwon, SK; Lee, SH; Lee, YH; Park, HK; Park, KS; Son, HS; Song, KH; Won, KC; Yu, JM | 1 |
Brown, K; Donato, AA | 1 |
Kang, SM; Lim, S; Sohn, M; Yun, HM | 1 |
Abdelrahman, KS; Abu-Hassan, AA; Alsaggaf, WT; El Hamd, MA; Soltan, OM | 1 |
Fuhr, U; Gründemann, D; Gu, Y; Hagos, Y; Hsin, CH; Jedlitschky, G; Kuehne, A | 1 |
Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N | 1 |
Arya, VV; Giri, R; Gofne, SK; Gupta, SK; Joglekar, SJ; Karnawat, SR; Kumar, SR; Kurmi, P; Lakhwani, LK; Mehta, SC; Mishra, A; Mohan, B; Murthy, LS; Patel, PM; Rajurkar, MN; Sahay, RK; Sawardekar, VM; Shembalkar, JV; Sonawane, AR; Soni, PN | 1 |
Jayabal, D; Jayanthi, S; Shimu, MSS; Thirumalaisamy, R | 1 |
Ahmed, M; Butt, TS; Ganesan, S; Khatri, M; Kumar, S; Madhurita, F; Nageeta, F; Patel, T; Sohail, R; Varrassi, G; Zafar, M; Zafar, W; Zaman, MU | 1 |
Atonal-Flores, B; Barranco-Juarez, A; León-Vázquez, ML | 1 |
Hong, JH; Lim, S; Moon, JS; Seong, K | 1 |
Ali, AM; Mostafa, MAA; Rabea, H; Salem, HF; Zakaraia, HG | 1 |
Ioji, T; Ishihara, H; Kosakai, Y; Watanabe, K; Yamaguchi, S | 1 |
Ahmed, S; Ali, SM; Baqar Abidi, SH; Kamal, J; Kanpurwala, MA; Khan, A; Khan, M; Khan, RA; Lohano, V; Mahmudi, NF; Saghir, M; Uddin, F | 1 |
Doubský, J; Douša, M; Gibala, P; Jireš, J; Kalášek, S; Kluk, A; Mervart, D; Pěček, D; Řezanka, P; Veseli, A | 1 |
39 review(s) available for metformin and sitagliptin phosphate
Article | Year |
---|---|
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2008 |
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Janumet: a combination product suitable for use in patients with Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles | 2008 |
New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2009 |
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss | 2010 |
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin and metformin--novel combination therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.
Topics: Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Metformin; Outcome Assessment, Health Care; Pioglitazone; Proinsulin; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
Topics: Adamantane; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sitagliptin Phosphate; Thiazolidinediones | 2015 |
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
Topics: Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Sitagliptin Phosphate; Triazines | 2015 |
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms; Weight Gain | 2016 |
Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Glargine; Liraglutide; Metformin; Patient Safety; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms | 2016 |
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy.
Topics: Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Metformin; Sitagliptin Phosphate | 2016 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Sitagliptin Phosphate; Sulfonylurea Compounds; Weight Loss; Young Adult | 2017 |
Ertugliflozin: First Global Approval.
Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States; United States Food and Drug Administration | 2018 |
Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Incidence; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome | 2019 |
Ertugliflozin for the treatment of type 2 diabetes.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
Topics: Anti-Inflammatory Agents; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Inflammation; Metformin; Pioglitazone; Risk Factors; SARS-CoV-2; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Weight Loss | 2021 |
Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Exenatide; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Metformin; Network Meta-Analysis; Sitagliptin Phosphate | 2022 |
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate | 2023 |
165 trial(s) available for metformin and sitagliptin phosphate
Article | Year |
---|---|
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Placebos; Proinsulin; Protease Inhibitors; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles | 2006 |
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Patient Selection; Placebos; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles | 2007 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2007 |
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha | 2010 |
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Topics: Administration, Oral; Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelial Cells; Enzyme Activation; Female; Hematopoietic Stem Cells; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pilot Projects; Pyrazines; Receptors, CXCR4; Sitagliptin Phosphate; Triazoles | 2010 |
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].
Topics: Adult; Aged; Aged, 80 and over; Belgium; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Triazoles; Young Adult | 2010 |
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pilot Projects; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Topics: Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Tablets; Therapeutic Equivalency; Treatment Outcome; Triazoles; United States; Young Adult | 2010 |
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2011 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2011 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].
Topics: Austria; Diabetes Mellitus, Type 2; Drug Tolerance; Female; Humans; Male; Metformin; Middle Aged; Prevalence; Primary Health Care; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain | 2011 |
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2011 |
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2012 |
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Stiffness; Young Adult | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2012 |
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles | 2012 |
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult | 2012 |
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult | 2013 |
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Topics: Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxidative Stress; Patient Compliance; Prospective Studies; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inflammation Mediators; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucose; Humans; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Kidney Transplantation; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2013 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2013 |
Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Metformin; Middle Aged; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Postmenopause; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Malondialdehyde; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
[Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sitagliptin Phosphate | 2015 |
Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glutamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Plasma Volume; Sitagliptin Phosphate; Treatment Outcome | 2014 |
The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Topics: Aged; Asia; Australia; Biomarkers; Biphasic Insulins; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Aspart; Insulin, Isophane; Male; Metformin; Middle Aged; Sitagliptin Phosphate; South America; Time Factors; Treatment Outcome | 2015 |
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Proinsulin; Pyrimidines; Sitagliptin Phosphate | 2015 |
Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Sitagliptin Phosphate; Sodium-Glucose Transport Proteins; Urinary Tract Infections | 2015 |
Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sitagliptin Phosphate | 2015 |
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds | 2015 |
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Weight Loss | 2015 |
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial.
Topics: Biomarkers; Blood Glucose; Clinical Protocols; Feasibility Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Metformin; Netherlands; Predictive Value of Tests; Research Design; Sitagliptin Phosphate; Stroke; Time Factors; Treatment Outcome | 2015 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Latin America; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2016 |
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2016 |
Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.
Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Obesity; Sitagliptin Phosphate; Treatment Outcome | 2016 |
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Nausea; Sitagliptin Phosphate; Treatment Outcome; Young Adult | 2016 |
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Male; Metformin; Middle Aged; Mycoses; Reproductive Tract Infections; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Urinary Tract Infections | 2016 |
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
Topics: China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2016 |
Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Nausea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2017 |
Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
Topics: Adult; Aged; Benzeneacetamides; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Enzyme Activators; Female; Glucokinase; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sitagliptin Phosphate | 2016 |
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Topics: Adamantane; Aged; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Exercise Therapy; Feedback, Physiological; Female; Glucagon-Like Peptide 1; Humans; Male; Meals; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2016 |
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
Topics: Adult; Aged; Aged, 80 and over; Asia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Nausea; North America; Sitagliptin Phosphate; Treatment Outcome | 2016 |
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Racial Groups; Sitagliptin Phosphate; Sulfonylurea Compounds; Weight Loss; Young Adult | 2016 |
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Topics: Aged; Bile Acids and Salts; Blood Glucose; Chenodeoxycholic Acid; Cholic Acid; Deoxycholic Acid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Feces; Female; Gallbladder; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Organ Size; Postprandial Period; Sitagliptin Phosphate; Sulfonylurea Compounds; Ultrasonography; Ursodeoxycholic Acid | 2016 |
Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Topics: Aged; Asian People; Blood Glucose; Cardiovascular Diseases; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2017 |
Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises.
Topics: Adolescent; Adult; Black or African American; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Longitudinal Studies; Male; Metformin; Middle Aged; Obesity; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Young Adult | 2016 |
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Topics: Age Factors; Aged; Blood Preservation; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Drug Therapy, Combination; Female; Fractures, Bone; Glycated Hemoglobin; Hip Fractures; Humans; Hypoglycemic Agents; Incidence; Insulin; Male; Metformin; Middle Aged; Osteoporotic Fractures; Proportional Hazards Models; Risk Factors; Sex Factors; Sitagliptin Phosphate; White People | 2017 |
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Antioxidants; Biomarkers; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium; Female; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Superoxide Dismutase; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2016 |
Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.
Topics: Asian People; China; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Topics: Adult; Aged; Benzofurans; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Enzyme Activators; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrimidines; Sitagliptin Phosphate | 2016 |
A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
Topics: Acarbose; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Piperazines; Republic of Korea; Sitagliptin Phosphate | 2017 |
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2017 |
Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
Topics: Adult; Aged; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Intercellular Adhesion Molecule-1; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vasodilation; Wisconsin; Young Adult | 2017 |
Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Dipeptidyl-Peptidase IV Inhibitors; Dyslipidemias; Female; Humans; Hypertension; Hypolipidemic Agents; Lipids; Male; Metformin; Middle Aged; Pakistan; Prospective Studies; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Weight Loss | 2016 |
Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate; Spleen; Thiazolidinediones; Tomography, X-Ray Computed | 2017 |
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Excipients; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Incretins; Injections, Jet; Male; Metformin; Middle Aged; Peptides; Sitagliptin Phosphate; Triglycerides; United States; Venoms | 2017 |
Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Topics: Benzofurans; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Hemoglobins, Abnormal; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Incretins; Male; Metformin; Middle Aged; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Sulfones; United States | 2017 |
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2017 |
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Topics: Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Treatment Outcome | 2018 |
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Topics: Adolescent; Adult; Body Mass Index; Diabetes, Gestational; Female; Glucose Intolerance; Humans; Metformin; Pilot Projects; Placebos; Pregnancy; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Young Adult | 2018 |
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aging; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Meals; Metformin; Risk; Sitagliptin Phosphate; Sweden | 2018 |
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucuronosyltransferase; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; UDP-Glucuronosyltransferase 1A9; Young Adult | 2019 |
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Republic of Korea; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Young Adult | 2018 |
THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Patient Discharge; Prospective Studies; Sitagliptin Phosphate | 2018 |
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Linear Models; Lipid Metabolism; Liraglutide; Male; Metformin; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Prognosis; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazoles; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidines; Treatment Failure | 2019 |
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Topics: Aged; Deprescriptions; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Least-Squares Analysis; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Dietary Fats; Drug Combinations; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Young Adult | 2019 |
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Prognosis; Sitagliptin Phosphate; Sulfonylurea Compounds | 2019 |
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Time Factors; Treatment Outcome | 2019 |
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds | 2019 |
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Metformin; Middle Aged; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2019 |
Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2019 |
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrans; Sitagliptin Phosphate | 2019 |
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
Topics: Area Under Curve; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Sitagliptin Phosphate; Triazines | 2020 |
Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Prognosis; Sitagliptin Phosphate | 2020 |
Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Pyrimidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome | 2020 |
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Topics: Adult; Aged; Biomarkers; Blood Glucose; Bone and Bones; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscles; Prognosis; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2021 |
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
Topics: Aged; Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet, Atherogenic; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Glucagon-Like Peptide-1 Receptor; Humans; Inflammation; Inflammation Mediators; Male; Metformin; Mice; Mice, Knockout; Middle Aged; Protein Isoforms; Sitagliptin Phosphate | 2020 |
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
Topics: Adult; Aged; Bile Acids and Salts; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; RNA, Ribosomal, 16S; Sitagliptin Phosphate; Sulfonylurea Compounds | 2021 |
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
SITAgliptin for Depressive Symptoms in Type 2 Diabetes: A Feasibility Randomized Controlled Trial.
Topics: Depression; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2021 |
Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
Topics: Blood Glucose; Brain Ischemia; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Ischemic Stroke; Metformin; Sitagliptin Phosphate; Stroke; Treatment Outcome | 2021 |
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2022 |
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
Topics: Administration, Oral; Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Patient Safety; Sitagliptin Phosphate; Treatment Outcome | 2022 |
Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study.
Topics: Area Under Curve; China; Cross-Over Studies; Fasting; Healthy Volunteers; Humans; Metformin; Sitagliptin Phosphate; Tablets; Therapeutic Equivalency | 2022 |
Analysis of pharmacoeconomic value of sitagliptin in the treatment of diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds | 2021 |
Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial).
Topics: Bone Morphogenetic Protein 15; Female; Fertilization; Growth Differentiation Factor 9; Humans; Leptin; Metformin; Polycystic Ovary Syndrome; RNA, Messenger; Sitagliptin Phosphate | 2022 |
Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Non-alcoholic Fatty Liver Disease; Prospective Studies; Sitagliptin Phosphate; Triglycerides | 2022 |
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Microvessels; Sitagliptin Phosphate; Sulfonylurea Compounds | 2022 |
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Preference; Pioglitazone; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Protease Inhibitors; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
Topics: Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome | 2023 |
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Rate; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney; Kidney Diseases; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate | 2023 |
Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Egypt; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2023 |
Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Prospective Studies; Quality of Life; Sitagliptin Phosphate | 2023 |
152 other study(ies) available for metformin and sitagliptin phosphate
Article | Year |
---|---|
Sitagliptin.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2007 |
New treatments for diabetes.
Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration | 2007 |
Sitagliptin/metformin (Janumet) for type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Janumet.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
[New class of oral antidiabetic drugs. Effective in combination with metformin].
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Treatment of type 2 diabetes mellitus and the incretin system.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms | 2007 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Type 2 diabetes: the end of clinical inertia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2007 |
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2007 |
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
Topics: Adolescent; Adult; Databases, Factual; Exenatide; Female; Glyburide; Humans; Hypoglycemic Agents; Insurance, Health; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Safety; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult | 2009 |
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Topics: Amyloid; Animals; Animals, Genetically Modified; Arginine; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Metformin; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2009 |
By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I
Topics: Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Drug Synergism; Europe; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Sulfonylurea Compounds; Triazoles | 2009 |
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2009 |
[Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles | 2009 |
[Combination antidiabetic therapy. Better control of blood glucose values].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2009 |
Initial therapy for type 2 diabetes. Examination of a combination approach.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Practice; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nurse Practitioners; Practice Guidelines as Topic; Primary Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Models, Theoretical; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Topics: Animals; Cardiovascular System; Coronary Vessels; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Deletion; Heart; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Pyrazines; Reference Values; Reperfusion; Sitagliptin Phosphate; Survivors; Triazoles | 2010 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters.
Topics: Adenylate Kinase; Animals; Biological Transport; Dogs; Hep G2 Cells; Humans; Kinetics; Metformin; Organic Cation Transporter 1; Phosphorylation; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
Topics: Animals; Caspase 3; ets-Domain Protein Elk-1; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Male; Metformin; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Rats, Zucker; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2011 |
Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry.
Topics: Animals; Blood Stains; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Humans; Hypoglycemic Agents; Lasers, Semiconductor; Metformin; Mice; Mice, Inbred C57BL; Molecular Structure; Pyrazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate; Species Specificity; Specimen Handling; Tandem Mass Spectrometry; Temperature; Triazoles | 2011 |
Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.
Topics: Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Indicators and Reagents; Metformin; Pharmaceutical Preparations; Pyrazines; Quality Control; Reproducibility of Results; Sitagliptin Phosphate; Triazoles | 2011 |
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; United Kingdom; Young Adult | 2012 |
The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Triazoles | 2012 |
Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.
Topics: Animals; Apolipoprotein B-100; Biological Transport; Biomarkers; Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Intestinal Absorption; Lipoproteins, HDL; Macrophages; Male; Metformin; Mice; Mice, Obese; Mice, Transgenic; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Choosing a blood-glucose-lowering agent after metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles | 2012 |
Association between sitagliptin adherence and self-monitoring of blood glucose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Child; Computer Simulation; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Logistic Models; Male; Medication Adherence; Metformin; Middle Aged; Odds Ratio; Predictive Value of Tests; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; United States; Young Adult | 2012 |
Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
Topics: Acetates; Anthraquinones; Azithromycin; Benzhydryl Compounds; Cinacalcet; Cloxacillin; Cresols; Cyclopropanes; Female; Fluorobenzenes; Humans; Hydrochlorothiazide; Losartan; Male; Metformin; Naphthalenes; Phenylpropanolamine; Piroxicam; Pyrazines; Pyrimidines; Quinolines; Rosuvastatin Calcium; Saliva; Sitagliptin Phosphate; Sulfides; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Triazoles | 2012 |
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Markov Chains; Metformin; Outcome Assessment, Health Care; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Length of Stay; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Pyrazines; Retrospective Studies; Secondary Prevention; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Substitution; Glucagon-Like Peptide 1; Glycemic Index; Health Care Costs; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Failure; Triazoles; United States | 2013 |
[Diabetes treatment in patients with chronic kidney disease].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Kidney Function Tests; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hypoglycemic Agents; Inflammation; Logistic Models; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hemizygote; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Metformin; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Pancreatitis; Plaque, Amyloid; Pyrazines; Random Allocation; Recombinant Proteins; Sitagliptin Phosphate; Time Factors; Triazoles | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
Sitagliptin: results from clinical practice.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2014 |
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Topics: Belgium; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles | 2013 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2013 |
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Keratins; Ki-67 Antigen; Male; Metformin; Pancreas, Exocrine; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Use of antidiabetic drugs in the U.S., 2003-2012.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States | 2014 |
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death.
Topics: Apoptosis; Daunorubicin; Hep G2 Cells; Humans; Hypoglycemic Agents; Metformin; NF-kappa B; Sitagliptin Phosphate; Tumor Suppressor Protein p53 | 2015 |
Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Propensity Score; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors | 2015 |
Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2015 |
A comparative study of smart spectrophotometric methods for simultaneous determination of sitagliptin phosphate and metformin hydrochloride in their binary mixture.
Topics: Drug Combinations; Hypoglycemic Agents; Limit of Detection; Metformin; Sitagliptin Phosphate; Spectrophotometry; Tablets | 2015 |
Development and Validation of a Method for Simultaneous Estimation of Metformin and Sitagliptin in Human Plasma by LC-MS-MS and Its Application in a Bioequivalence Study.
Topics: Chromatography, Liquid; Drug Stability; Humans; Metformin; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate; Tandem Mass Spectrometry; Therapeutic Equivalency | 2015 |
Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemoglobin A; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate | 2015 |
Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: findings from a national health plan.
Topics: Adult; Aged; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Drug Utilization; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; National Health Programs; Sitagliptin Phosphate | 2015 |
Analysis of metformin, sitagliptin and creatinine in human dried blood spots.
Topics: Creatinine; Diabetes Mellitus; Dried Blood Spot Testing; Drug Stability; Humans; Hypoglycemic Agents; Linear Models; Metformin; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate | 2015 |
Developing imprinted polymer nanoparticles for the selective separation of antidiabetic drugs.
Topics: Biomimetic Materials; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Metformin; Microscopy, Atomic Force; Molecular Imprinting; Nanoparticles; Polymerization; Polymers; Sitagliptin Phosphate; Spectroscopy, Fourier Transform Infrared; Surface Properties | 2015 |
[Effective prevention of coronary heart disease by early diabetes therapy].
Topics: Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early Medical Intervention; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2015 |
Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Sitagliptin Phosphate; Thiazolidinediones | 2015 |
Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study.
Topics: Adipose Tissue; Adiposity; Adolescent; Adult; Aged; Body Composition; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electric Impedance; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Obesity; Pericardium; Pilot Projects; Sitagliptin Phosphate; Young Adult | 2016 |
Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
Topics: Biomarkers; Blood Glucose; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Substitution; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Liraglutide; Meta-Analysis as Topic; Metformin; Models, Economic; National Health Programs; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Treatment Outcome | 2016 |
[Impact of sitagliptin on aspirin resistance in patients with Type 2 diabetes mellitus].
Topics: Aspirin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Resistance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Sitagliptin Phosphate | 2015 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference | 2016 |
Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Sitagliptin Phosphate | 2016 |
Effects of Epothilone A in Combination with the Antidiabetic Drugs Metformin and Sitagliptin in HepG2 Human Hepatocellular Cancer Cells: Role of Transcriptional Factors NF-κB and p53.
Topics: Antineoplastic Agents; Apoptosis; Benzoxazoles; Carcinoma, Hepatocellular; Dactinomycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Epothilones; Hep G2 Cells; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; NF-kappa B; Sitagliptin Phosphate; Tumor Suppressor Protein p53 | 2016 |
[One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination].
Topics: Adult; Aged; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Combinations; Female; Humans; Hungary; Hypoglycemic Agents; Linear Models; Male; Medication Adherence; Metformin; Middle Aged; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2016 |
Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Topics: Aged; Blood Glucose; Canada; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2016 |
LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction.
Topics: Chromatography, Liquid; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Solid Phase Extraction; Therapeutic Equivalency | 2016 |
Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
Topics: Aged; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Medication Adherence; Metformin; Middle Aged; Propensity Score; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Withholding Treatment | 2017 |
Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin.
Topics: Aged; Alopecia; Diabetes Mellitus, Type 2; Eyebrows; Eyelashes; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Treatment Outcome | 2017 |
Diabetes prescribing rises by a third over five years.
Topics: Diabetes Mellitus, Type 2; Drug Prescriptions; England; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate | 2016 |
Management of Sitagliptin and Metformin Combination Toxic Overdose.
Topics: Acidosis, Lactic; Adult; Drug Overdose; Female; Humans; Metformin; Sitagliptin Phosphate; Suicide, Attempted | 2016 |
C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Weight Loss | 2016 |
Metformin-Induced Generalized Fixed Drug Eruption With Cutaneous Hemophagocytosis.
Topics: Aged, 80 and over; Biopsy; Diabetes Mellitus, Type 2; Drug Eruptions; Drug Substitution; Histiocytes; Humans; Hypoglycemic Agents; Immunohistochemistry; Lymphocytes; Lymphohistiocytosis, Hemophagocytic; Lymphoid Enhancer-Binding Factor 1; Male; Metformin; Sitagliptin Phosphate; Skin; Treatment Outcome | 2017 |
Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress.
Topics: Animals; Behavior, Animal; Biomarkers; Chronic Disease; Depression; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Gene Expression Regulation, Enzymologic; Insulin Resistance; Liver; Male; Metformin; Mitogen-Activated Protein Kinase 8; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Signal Transduction; Sitagliptin Phosphate; Stress, Psychological; Time Factors | 2017 |
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on m
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heterocyclic Compounds, 2-Ring; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrans; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse.
Topics: Adult; Aged; Consolidation Chemotherapy; Critical Pathways; Diabetes Mellitus, Type 2; Electronic Health Records; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Machine Learning; Male; Metformin; Middle Aged; Proportional Hazards Models; Sitagliptin Phosphate | 2016 |
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Recombinant Fusion Proteins; Sitagliptin Phosphate; Venoms | 2017 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients.
Topics: Adult; Atherosclerosis; Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Interleukin-6; Lipid Metabolism; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Thiazolidinediones | 2017 |
A Versatile Liquid Chromatographic Method for the Simultaneous Determination of Metformin, Sitagliptin, Simvastatin, and Ezetimibe in Different Dosage Forms.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Ezetimibe; Limit of Detection; Metformin; Simvastatin; Sitagliptin Phosphate | 2018 |
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2017 |
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Insulin Resistance; Leptin; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Sitagliptin Phosphate; Triglycerides | 2017 |
Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Macular Edema; Metformin; Middle Aged; Sitagliptin Phosphate | 2018 |
An Evidence Based Study on Comparison of Adverse Drug Reactions of Metformin & Sitagliptin with their Combination.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Metformin; Sitagliptin Phosphate | 2016 |
Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Sitagliptin Phosphate | 2018 |
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2018 |
Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model.
Topics: Adipokines; Animals; Blood Glucose; Body Mass Index; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin Resistance; Lipids; Liraglutide; Male; Metformin; Rats; Rats, Wistar; Retinol-Binding Proteins; Sitagliptin Phosphate; Streptozocin | 2018 |
Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Apoptosis; Biomarkers; Blood Glucose; Body Weight; Collagen; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Fatty Acids; Glucagon-Like Peptide 1; Glycogen Synthase Kinase 3 beta; Male; Metformin; Mitogen-Activated Protein Kinase 14; Myocardium; Organ Size; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats, Wistar; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate | 2018 |
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
Topics: Adult; Benzhydryl Compounds; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Medicare Part D; Metformin; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Sitagliptin Phosphate; United States | 2019 |
THE CIRCLE OF CARE IN DIABETES: FROM HOME TO HOSPITAL TO HOME.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Metformin; Patient Discharge; Sitagliptin Phosphate | 2018 |
Side effects of frequently used oral antidiabetics on wound healing in vitro.
Topics: Administration, Oral; Apoptosis; Carbamates; Caspases; Cell Line; Endopeptidases; Fibroblasts; Gelatinases; Glyburide; Humans; Hypoglycemic Agents; Keratinocytes; Membrane Proteins; Metformin; Piperidines; Receptors, CXCR4; Serine Endopeptidases; Sitagliptin Phosphate; Wound Healing | 2019 |
Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
Topics: Adult; Aged; Blood Glucose; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Costs; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Metformin; Middle Aged; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2019 |
Reply.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
The Future of the GLP-1 Receptor Agonists.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2019 |
Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration.
Topics: Animals; Horses; Hypoglycemic Agents; Incretins; Insulin; Metformin; Sitagliptin Phosphate | 2019 |
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Incretins; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy.
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones | 2019 |
A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.
Topics: Biological Assay; Humans; Hydrophobic and Hydrophilic Interactions; Metformin; Plasma; Reproducibility of Results; Sitagliptin Phosphate; Tandem Mass Spectrometry | 2019 |
Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19.
Topics: Animals; Apoptosis; Cells, Cultured; DNA (Cytosine-5-)-Methyltransferase 1; Drug Therapy, Combination; Female; Gonadal Steroid Hormones; Granulosa Cells; Insulin; Insulin Resistance; Luteinizing Hormone; Metformin; Phosphatidylinositol 3-Kinases; Phosphorylation; Polycystic Ovary Syndrome; Progesterone; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; RNA, Long Noncoding; Sitagliptin Phosphate | 2019 |
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2019 |
Sitagliptin favorably modulates immune-relevant pathways in human beta cells.
Topics: Cell Line; Diabetes Mellitus, Type 2; Gene Expression; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunologic Factors; Inflammation; Insulin-Secreting Cells; Interleukin-6; Liraglutide; Metformin; Signal Transduction; Sitagliptin Phosphate; Tumor Necrosis Factor-alpha; Up-Regulation | 2019 |
Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2020 |
Reply.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2020 |
Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study.
Topics: Adult; Alberta; Cohort Studies; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Logistic Models; Male; Metformin; Middle Aged; Retrospective Studies; Sitagliptin Phosphate | 2020 |
Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.
Topics: Acarbose; Animals; Bacteria; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Feces; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Male; Metagenomics; Metformin; Rats; Rats, Zucker; RNA, Ribosomal, 16S; Sitagliptin Phosphate | 2019 |
Metformin Hydrochloride and Sitagliptin Phosphate Fixed-Dose Combination Product Prepared Using Melt Granulation Continuous Processing Technology.
Topics: Chemistry, Pharmaceutical; Drug Combinations; Humans; Metformin; Sitagliptin Phosphate; Transition Temperature | 2019 |
Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes.
Topics: Bone Density; Cancellous Bone; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Postmenopause; Sitagliptin Phosphate | 2019 |
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
Topics: Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Resistance; Male; Metformin; Middle Aged; Prognosis; Pyrimidines; Republic of Korea; Sitagliptin Phosphate; Thiazolidinediones | 2020 |
Simultaneous ultra-trace quantitative colorimetric determination of antidiabetic drugs based on gold nanoparticles aggregation using multivariate calibration and neural network methods.
Topics: Analysis of Variance; Calibration; Colorimetry; Gold; Hypoglycemic Agents; Least-Squares Analysis; Metal Nanoparticles; Metformin; Multivariate Analysis; Neural Networks, Computer; Reproducibility of Results; Sitagliptin Phosphate; Spectrophotometry, Ultraviolet | 2020 |
Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2020 |
Effects of Metformin and Sitagliptin Monotherapy on Expression of Intestinal and Renal Sweet Taste Receptors and Glucose Transporters in a Rat Model of Type 2 Diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose Transport Proteins, Facilitative; Insulin Resistance; Intestine, Small; Kidney; Metformin; Rats, Zucker; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate; Taste | 2020 |
Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI.
Topics: Adult; Female; Humans; Metformin; Oocytes; Polycystic Ovary Syndrome; Sitagliptin Phosphate; Sperm Injections, Intracytoplasmic | 2021 |
Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2020 |
Oral anti-diabetic drugs as endocrine disruptors in vitro - No evidence for additive effects in binary mixtures.
Topics: Administration, Oral; Cell Line; Chromatography, Liquid; Drug Interactions; Endocrine Disruptors; Humans; Hypoglycemic Agents; Metformin; Simvastatin; Sitagliptin Phosphate; Steroids; Sulfonylurea Compounds; Tandem Mass Spectrometry | 2021 |
Sitagliptin/Metformin: A New Medical Treatment in Polycystic Ovary Syndrome.
Topics: Female; Humans; Menstrual Cycle; Metformin; Ovulation; Polycystic Ovary Syndrome; Sitagliptin Phosphate | 2020 |
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate | 2021 |
Pharmacoeconomic Analysis of Sitagliptin/Metformin for the Treatment of Type 2 Diabetes Mellitus: A Cost-Effectiveness Study.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Ecuador; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate | 2021 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate | 2022 |
Analysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and Optimization.
Topics: Chromatography, High Pressure Liquid; Counterfeit Drugs; Dipeptidyl-Peptidase IV Inhibitors; Humans; Metformin; Sitagliptin Phosphate | 2021 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |
Coadministration of sitagliptin or metformin has no major impact on the adverse metabolic outcomes induced by dexamethasone treatment in rats.
Topics: Animals; Blood Glucose; Body Weight; Dexamethasone; Diabetes Mellitus, Experimental; Feeding Behavior; Glucose Tolerance Test; Hypoglycemic Agents; Male; Metformin; Rats; Rats, Wistar; Sitagliptin Phosphate | 2021 |
Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
Topics: Cerebrovascular Disorders; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2022 |
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Topics: Administration, Oral; Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Patient Safety; Sitagliptin Phosphate; Treatment Outcome | 2022 |
Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2022 |
Spectrophotometric Determination of Metformin in Different Pharmaceutical Combinations With Glipizide or Sitagliptin in Presence of Toxic Impurities of Metformin.
Topics: Glipizide; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Tablets | 2022 |
Validation of a rapid and economical RP-HPLC method for simultaneous determination of metformin hydrochloride and sitagliptin phosphate monohydrate: Greenness evaluation using AGREE score.
Topics: Chromatography, High Pressure Liquid; Green Chemistry Technology; Hypoglycemic Agents; Limit of Detection; Metformin; Reproducibility of Results; Sitagliptin Phosphate; Software | 2022 |
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Humans; Inflammation; Insulin Resistance; Liver Cirrhosis; Metabolic Syndrome; Metformin; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Sitagliptin Phosphate; Transaminases | 2022 |
[Imeglimin: features of the mechanism of action and potential benefits].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Sitagliptin Phosphate; Triazines | 2022 |
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.
Topics: Acarbose; Animals; Hypoglycemic Agents; Immune Checkpoint Inhibitors; Insulin; Melanoma; Metformin; Mice; Pioglitazone; Sitagliptin Phosphate | 2022 |
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Prospective Studies; Sitagliptin Phosphate; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Development of extended-release metformin core tablet and synergistic coating of sitagliptin for the treatment of type-II diabetes mellitus - A comparative drug release evaluation with reference product.
Topics: Diabetes Mellitus, Type 2; Drug Liberation; Humans; Metformin; Polymers; Sitagliptin Phosphate; Tablets | 2022 |
Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study.
Topics: Blood Glucose; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Quality of Life; Sitagliptin Phosphate | 2023 |
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
A new application of isoindole fluorophore derivative in sitagliptin antidiabetic medication assay: Application to dosage forms and biological fluid evaluation.
Topics: Humans; Hypoglycemic Agents; Metformin; o-Phthalaldehyde; Sitagliptin Phosphate; Spectrometry, Fluorescence; Sulfhydryl Compounds | 2023 |
In vitro validation of an in vivo phenotyping drug cocktail for major drug transporters in humans.
Topics: Biological Transport; Drug Interactions; HEK293 Cells; Humans; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 2; Sitagliptin Phosphate | 2023 |
Molecular insights of anti-diabetic compounds and its hyaluronic acid conjugates against aldose reductase enzyme through molecular modeling and simulations study-a novel treatment option for inflammatory diabetes.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Humans; Hyaluronic Acid; Inflammation; Insulin Resistance; Ligands; Metformin; Molecular Docking Simulation; Molecular Dynamics Simulation; Phenformin; Sitagliptin Phosphate | 2023 |
[Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Longitudinal Studies; Male; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2023 |
Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; East Asian People; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Obesity; Sitagliptin Phosphate; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Treatment Outcome | 2023 |
Comprehensive UHPLC-MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation.
Topics: Chromatography, High Pressure Liquid; Drug Compounding; Metformin; Nitrosamines; Pharmaceutical Preparations; Pyrazines; Sitagliptin Phosphate | 2024 |